Signant’s Anthony Everhart discusses that when it comes to maintaining accuracy and precision in clinical trials during the pandemic, it’s important to consider endpoint data and methods for validity. In general, there are two primary approaches: simplification and modification.

The white paper details the three key considerations with simplification:

• Determine endpoint data risks
• Modify the protocol to collect less data
• Consult with the right committees

The paper argues that rapid modernization and decentralization of clinical trials should become more of the norm even beyond COVID-19.